Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

USANA Health (USJ) Stock Price & Analysis

USJ Stock Chart & Stats

€12.30-€0.60(-4.65%)
At close: 1:00 AM GMT+1
€15€15.5€1612 May22 Jun
Day’s Range
EUR 12.30 - EUR 12.60
52-Week Range
EUR 10.50 - EUR 20.00
Previous Close
EUR 12.90
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 236.74M
Enterprise Value
EUR 273.74M
Total Cash (Recent Filing)
EUR 168.56M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.69
Next Earnings
Nov 03, 2026 (Est.)
EPS Estimate
0.1
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet

Substantial cash and no debt give USANA financial flexibility while profitability is under pressure. Positive free cash flow can support product investment, retail expansion, and brand development without relying heavily on borrowing or refinancing.

Product And Retail Expansion

New product launches and broader retail distribution diversify USANA beyond its traditional direct-selling channel. If adoption continues, these initiatives can expand customer acquisition, improve brand visibility, and create additional routes to durable revenue growth.

Core Business And China Resilience

Stability in the core nutrition business provides an earnings foundation while newer brands develop. Renewed momentum in Mainland China, supported by product launches and incentives, suggests the established brand-partner network can still generate demand in important markets.

Bears Say

Severe Profitability Deterioration

The sharp decline in operating and net profitability reduces the earnings power of USANA's established sales base. Even with strong gross margins, near-zero EBIT leaves little cushion for marketing, operating, tax, or execution pressures and weakens sustainable cash conversion.

Impairment And Lowered Outlook

The guidance reduction and large Hiya impairment indicate that the venture portfolio is producing weaker near-term economics than previously expected. This raises execution concerns, reduces reported earnings, and may constrain confidence in the pace and returns of future growth investments.

Revenue And Customer Contraction

Broad declines across sales and customer measures threaten operating leverage because USANA depends on recurring purchases from customers and distributor networks. Persistent contraction would make fixed costs harder to absorb and limit the benefits of product and channel expansion.

USANA Health News

USJ FAQ

What was USANA Health’s price range in the past 12 months?
USANA Health lowest stock price was €10.50 and its highest was €20.00 in the past 12 months.
What is USANA Health’s market cap?
USANA Health’s market cap is €236.74M.
When is USANA Health’s upcoming earnings report date?
USANA Health’s next earnings report is estimated for Nov 03, 2026 (not yet confirmed), which is today.
How were USANA Health’s earnings last quarter?
USANA Health released its earnings results on Aug 04, 2026. The company reported -€0.062 earnings per share for the quarter, missing the consensus estimate of €0.383 by -€0.446.
Is USANA Health overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does USANA Health pay dividends?
USANA Health does not currently pay dividends.
What is USANA Health’s EPS estimate?
USANA Health’s EPS estimate is 0.10.
How many shares outstanding does USANA Health have?
USANA Health has 18,476,534 shares outstanding.
What happened to USANA Health’s price movement after its last earnings report?
USANA Health reported an EPS of -€0.062 in its last earnings report, missing expectations of €0.383. Following the earnings report the stock price went down -19.792%.
Which hedge fund is a major shareholder of USANA Health?
Hedge funds hold USANA Health shares: the largest hedge-fund position in USANA Health is 455,704,000 shares, and hedge funds increased their holdings by 92.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology